Market Eyes LiveIncyte Genomics Inc (INCY) Stock Rating & Analysis
MELANY's data-driven read on Incyte Genomics Inc.
Why INCY scores 71/100
MELANY scores Incyte Genomics Inc 71/100 by weighing eight factors. Here is how INCY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 17.2x vs sector 22.0x median
Margins, returns on capital, and balance-sheet strength.
- Gross margin 56%
- ROE 31%
Direction and relative strength of the recent share-price trend.
- Price +8.7% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +25%
What Wall Street price targets and revisions are signalling.
- Institutional net buying +11.0%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for INCY
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Incyte Genomics Inc sits in the Healthcare sector theme, which MELANY currently rates 38/100 for strength. Theme strength feeds INCY's momentum and catalyst factors above.
INCY trade plan (members only)
MELANY has a full position plan for Incyte Genomics Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates INCY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Incyte Genomics Inc's 71/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about INCY
Is Incyte Genomics Inc (INCY) a buy?
As of 2026-08-10, MELANY rated Incyte Genomics Inc Highest Conviction with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Incyte Genomics Inc's MELANY score?
Incyte Genomics Inc (INCY) has a MELANY composite score of 71/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the INCY stock rating calculated?
MELANY scores INCY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Incyte Genomics Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Incyte Genomics Inc (INCY) Highest Conviction with a composite of 71/100 as of 2026-08-10. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the INCY stock price forecast?
MELANY does not publish price targets or forecasts for INCY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for Incyte Genomics Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is INCY stock overvalued or undervalued?
MELANY's valuation factor currently reads 56/100 for Incyte Genomics Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives INCY's read.
What price should I buy INCY at?
Rather than chasing the current price, MELANY computes a smart entry zone for INCY: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying INCY stock?
The top risks MELANY currently flags for Incyte Genomics Inc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Incyte Genomics Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 89/100 for Incyte Genomics Inc, and earnings track record, at 94/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will INCY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 78/100 for INCY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this INCY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-10. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores INCY continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
INCY's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.